Not So Different: A Podcast From The Center For Biosimilars

Show Notes FDA Approves First MS Biosimilar Stelara and Enbrel Chosen for IRA Price Negotiation Biocon Biosimilar Quarterly Sales Up 106% STADA Earnings Project Record Breaking Profits for 2023 Despite Global Increase in Amjevita Sales, US Sales Dropped 63% Authors Suggest Major Policy Shifts to Boost Biosimilar Development, Accessibility Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry